Expert Ratings for Verona Pharma
Portfolio Pulse from Benzinga Insights
Verona Pharma (NASDAQ:VRNA) has received predominantly bullish ratings from analysts in the last quarter, with 5 bullish and 1 somewhat bullish ratings. The average 12-month price target for the stock, according to 6 analysts, is $32.17, marking a 14.89% increase over the past month.
September 01, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verona Pharma has received positive analyst ratings, with an increased 12-month price target, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. In this case, the predominantly bullish ratings and increased price target for Verona Pharma suggest a positive outlook for the stock, which could lead to increased demand and a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100